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Abstract 
 
Background 
The use of left ventricular assist device (LVAD) has emerged as a popular 
treatment for patients with advanced heart failure. It is not uncommon for these 
patients to suffer from renal failure requiring renal replacement therapy. The 
purpose of this study is to assess hemodynamic parameters and ability to 
complete the prescribed hemodialysis session in a series of patients who 
underwent numerous dialysis treatments.   
Methods 
Nine patients with Heart Mate II LVAD received 170 intermittent inpatient 
hemodialysis treatments between January 1, 2010 and December 31, 2012. 
Assessment included vital signs, ultrafiltrate removed, hemodialysis duration, 
symptoms, early terminations (ET), and adverse events during each hemodialysis 
session.   
Results 
The mean age was 53 ± 18 with a range of 26-83 years, with a male 
predominance (7/9). Indication for LVAD was as destination therapy (DT) in the 
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majority of patients (6/9). Nine patients who received a total of 170 hemodialysis 
sessions with a mean prescribed and achieved: ultrafiltration (liters) 1.98 ± 1.5 and 
1.90 ± 1.6; hemodialysis duration (hours) 3.12 ± 0.3 and 2.86 ± 0.9, respectively. 
Early termination was experienced in 11 sessions (6.5%). Causes of ET were 
hypotension in 72.7%, other causes were equally distributed between clotted 
extra-corporeal circuits, nausea & vomiting and LVAD alarm (9.1% in each). 
Serious arrhythmias were not observed in any of the hemodialysis treatments. Six 
out of nine patients (66.7%) recovered kidney function and became dialysis 
independent. 
Conclusion 
In a hospital setting, patients with LVAD can often tolerate and complete the 
prescribed hemodialysis treatment.  
Keywords: Hemodialysis, Heart failure, Kidney failure, Hemodynamic instability, 
LVAD 
 
Introduction 
 
Roughly 5.7 million individuals in the United States live with heart failure (HF), 10% 
of which are considered to be advanced and non-responsive to conventional 
therapies [1]. HF can be associated with cardio-renal syndrome; a bidirectional 
and dysfunctional interaction between heart and kidneys in which therapy to 
relieve HF is limited by worsening renal function [2].  In the US, over 1 million 
patients are hospitalized annually for acute decompensated HF and 27-40% of 
these patients develop acute kidney injury (AKI) [3]. Sixty-three percent of patients 
hospitalized with congestive heart failure meet the National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative (K/DOQI) definition of Stage 3-5 
chronic kidney disease (CKD) [4]. 
The number of patients with advanced heart failure that has become unresponsive 
to conventional medical therapy is increasing rapidly. One of the most promising 
new alternatives to heart transplantation is use of ventricular assist devices [5]. 
Left ventricular assist devices (LVADs) draw blood from the left ventricle and 
delivers it directly into the ascending aorta. Recently, it has emerged as a common 
therapy for patients with acute or chronic severe HF. It can be used as a bridge to 
transplantation or as a destination therapy (i.e., for circulatory support with no 
intention of transplantation). According to the Interagency Registry for 
Mechanically Assisted Circulatory Support (INTERMACS), more than 15,000 VAD 
implants were performed between 2006 and 2015 [6]. Due to the limited number of 
heart transplants that can be performed each year and the improved efficacy of 
LVAD as destination therapy, LVAD implantation frequency increased 
exponentially each year. For example, 206 VAD implants were performed in 2006 
as compared to more than 2500 in 2013 [6]. 
Decompensated HF patients with renal failure may require renal replacement 
therapy (RRT) until kidney function recovers. In one study, of 107 consecutive 
patients who underwent HeartMate II implantation, 14% required RRT [7].  The 
majority of these patients are managed on an inpatient basis which results in 
 
 
 
 
The VAD Journal: https://doi.org/10.13023/VAD.2016.25 Page 3 of 11 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
intensive nursing care and accrual of high medical cost. In 2010, Medicare 
expenditures for patients with both CKD and HF totaled over $19.4 billion [8]. 
There is limited information in the literature about the tolerability of these patients 
to intermittent hemodialysis (IHD). The purpose of this study is to describe the 
experience in a cohort of patients who received LVAD and underwent a rather 
large number of IHD treatments in a single medical center. 
Methods 
Research Design and Data Collection 
Information on patient demographics, medical history, and dialysis prescriptions 
were retrospectively obtained using the electronic medical record. Each IHD 
session flowsheet was individually reviewed, and the following data were recorded: 
blood pressure (BP), heart rate (HR), ultrafiltrate (UF) removed, dialysis duration, 
and symptoms documented by nursing staff.  If blood pressure could be obtained 
by cuff, mean arterial pressure (MAP) was calculated as the sum of 1/3 systolic 
blood pressure (SBP) and 2/3 diastolic blood pressure (DBP). Doppler assessment 
of MAP was utilized in the majority of the cases [9]. Beside Doppler 
measurements, the nursing staff relied on patient symptoms and the continuous 
hemodynamic parameters of the LVAD apparatus for clinical assessment. HR was 
assessed by reviewing the rhythm on a telemetry monitor.   
All patients were dialyzed with a Gambro Revaclear dialysis membrane (Opelika, 
AL) with a 2.25mEq/L calcium dialysate at 37ºC.  The University of Kentucky 
Institutional Review Board approved the study protocol.  Consent was waived 
given the retrospective nature of the study.  
Participants and Settings 
Patients included in the study received IHD between January 1, 2010 and 
December 31, 2012, and were selected using the procedural terminology (CPT) 
codes for LVAD and IHD. They were more than 18 years of age and received a 
HeartMate II® left ventricular assist system (Thoratec® Corporation, Pleasanton, 
CA). At the time of this study, the HeartMate II LVAD was the most commonly 
used continuous-flow pump for destination therapy in HF [10].   
The HeartMate II® flow setting were predetermined by the LVAD nurse and not 
altered by the IHD staff. Throughout the dialysis treatment, patients were observed 
via telemetry, and LVAD-parameters monitor, which included pump speed (range 
8600 to 9800 rpm), power, and pulsatility-index (PI). PI, an inverse measure of 
assistance provided by the continuous-flow pump, is an indicator of decreased 
circulating blood volume. LVAD nurses were instructed to use the parameters, 
including PI, in addition to a drop in MAP below 60 mmHg to notify the dialysis 
staff of hemodynamically significant events [10]. 
Results 
Nine patients who received a total of 170 IHD sessions were identified. The mean 
age was 53 ± 18 with a range of 26-83 years, with a male predominance (7/9). The 
majority of patients (6/9) did not have prior known CKD. Indication for LVAD was 
as destination therapy (DT) in the majority of patients (6/9). All patients who were 
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bridged-to-transplant (BTT) ultimately received cardiac transplantation (3/3). Time 
to IHD post-LVAD insertion was quite varied, with only 3 patients started on IHD 
within 2 weeks of implantation. Approximately 2/3 of the IHD sessions were 
performed in an ICU setting. In this series the longest period of time that a patient 
was maintained continuously on IHD was slightly greater than 2 months. Of 
interest, the majority of patients (6/9) recovered kidney function and became 
dialysis independent (Table 1). The mean pre- and post IHD systolic blood 
pressures were 98 ± 13 mmHg (range: 77-116) and 98 ± 13 mmHg (range: 83-
119). The average blood flow rates during dialysis were 347 ± 55 mL/min.  
 
Table 1. Demographic and clinical characteristics of Patients 
 
Patient Age  Sex Prior CKD DM HTN 
HD 
initiation 
post 
LVAD 
implanta-
tion 
(days) 
Days on 
HD with 
LVAD 
Renal Function 
Recovered 
BTT/DT
* 
Final Status 
1 70 M Yes Yes Yes 24 3 Yes DT Deceased  
2A 26 M No No No 185 10 Yes BTT Alive with LVAD  
2B 26 M No No No 225 16 Yes BTT Alive/LVAD Explant 
3 51 M No No No 6 65 Yes DT Deceased 
4 44 F No No Yes 67 60 No DT Deceased 
5 68 F No No Yes 5 1 No DT Deceased 
6 56 M Yes Yes Yes 5 37 Yes BTT Alive/Transplant 
7 41 M No No Yes 16 57 No DT Deceased 
8 41 M No No No 109 42 Yes BTT Alive/Transplant 
9A 83 M Yes No Yes 15 22 Yes DT Alive with LVAD  
9B 83 M Yes No Yes 443 42 No DT Deceased 
*BTT – Bridge to Transplant; DT – Destination Therapy 
 
In the 9 reported patients there were 11 defined hemodialysis periods as patient 
#2 and patient #9 had two distinct time frames on IHD that were separated by 1 
and 13 months respectively. On average, patients received 16 ± 13 IHD 
treatments, with a median of 11 sessions. The average hemodialysis prescription 
across all 9 patients was 3.12 ± 0.3 hours and 1.98 ± 1.5 liters of UF.  Actual 
achieved dialysis therapy duration was 2.86 ± 0.9 hours and UF was 1.90 ± 1.6 
liters (Table 2).  
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Table 2. Hemodialysis Characteristics per Patient  
 
* Number of HD treatments that were terminated ≥ 15 minutes before the end of the 
prescribed HD duration (percent of all treatments that were terminated early). 
** Number of HD treatments when the patient did not achieve ≥ 250 mL of the prescribed 
UF (percent of all treatments) 
 
Of the total 170 IHD treatments, LVAD parameters did not reveal any low-flow 
event (as defined by PI) and only one of the 170 sessions was terminated due to 
LVAD alarm. Nausea or emesis was experienced in 1.9 % of the IHD sessions. 
The most common intervention for hemodynamic instability events was the 
administration of albumin, which was primarily given for hypotension. There were 
11 sessions (6.5%) when dialysis was terminated early. Early termination (ET) was 
defined as those sessions when IHD was terminated ≥ 15 minutes before the end 
of the prescribed IHD duration. On average, ET sessions were reduced by 60 
minutes and varied in time post-LVAD implantation from 5-191 days (Table 3). 
Causes of ET were hypotension in 72.7%, other causes were equally distributed 
between clotted dialysis, nausea & vomiting and LVAD alarm (9.1% in each) 
Patient 
# HD 
Sessions 
Average HD 
Duration  
Prescribed 
(hrs) 
Average HD 
Duration 
Achieved 
(hrs) 
# of Early 
Termination 
(%)* 
Average 
Prescribed UF 
(L) 
Average Net 
UF (L)  
# of HD 
sessions with 
UF not 
achieved (%)** 
1 3 3.0 3.0 0 (0%) 0.7  0.7  0 (0%) 
2A 5 3.0 2.3 3 (60%) 1.8 1.6  2 (40%) 
2B 7 2.9 2.9 0 (0%) 0.5 0.7  0 (0%) 
3 32 3.4 3.4 1 (3%) 2.4  2.3  9 (28%) 
4 33 3.2 3.2 2 (6%) 4.6  4.5  7 (21%) 
5 1 2.5 0.5 1 (100%) 1.5  0.5  1 (100%) 
6 17 3.6 3.5 1 (6%) 0.3  0.3  1 (6%) 
7 32 3.5 3.4 3 (9%) 4.3  4.3  4 (13%) 
8 21 3.2 3.2 0 (0%) 2.9  2.9  1 (5%) 
9A 8 3.2 3.3 0 (0%) 2.8  2.8  0 (0%) 
9B 11 3.0 3.0 0 (0%) 0.9  0.9  2 (19%) 
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(Table 3). Failure to achieve the prescribed UF by ≥ 250 mL occurred in 27 of the 
170 sessions (15.9%) and averaged roughly 1,000 mL (Table 2).  
Table 3. Detailed analysis of early terminated hemodialysis sessions  
Patient 
# of Early 
Terminations 
Per Patient 
Reduced HD 
Time (min) 
Time since 
LVAD 
Insertion 
(days) 
Reason of HD Termination 
2A T1 60 185 Asymptomatic Hypotension 
  T2 90 189 Symptomatic Hypotension 
  T3 60 191 Asymptomatic Hypotension 
       
3 T1 15 14 Clotted Dialyzer 
       
4 T1 30 103 Asymptomatic Hypotension 
  T2 30 115 Nausea and Vomiting 
       
5 T1 120 5 Symptomatic Hypotension 
       
6 T1 105 17 LVAD Alarm  
       
7 T1 30 50 Symptomatic Hypotension 
  T2 45 62 Symptomatic Hypotension 
  T3 120 66 Symptomatic Hypotension 
 
Inability to register BP using standard sphygmomanometer due to LVAD-induced 
reduction in pulse pressure was observed in 6 of the 9 patients at some point 
throughout the course of their IHD sessions. During these episodes patients were 
mostly asymptomatic with minimal increase in HR or cardiac rhythm changes 
(assessed by telemetry monitoring) and had no change in mental status.   
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Discussion 
This retrospective study details the hemodialysis parameters and overall 
tolerability in patients with LVAD requiring post-implantation IHD. There were very 
few reported adverse events and ET of dialysis occurred in less than 10% of 
treatments. The majority of patients achieved the prescribed ultrafiltration. All 
patients that were BTT recovered kidney function prior to transplantation. 
All but 1 of the patients included in this study were monitored while receiving IHD 
within the ICU. This allowed for more frequent cardiac monitoring in addition to the 
availability of inotropic agents. Although a MAP < 60 mmHg was experienced at 
some point through the course of IHD for each patient (on average 48% of the 
time) the intensive monitoring and availability of cardiac vasopressors allowed for 
largely uneventful IHD sessions. 
A minor portion of sessions requiring ET or adjustment of dialysis were mainly due 
to episodes of asymptomatic hypotension. Hypotension in dialysis is multifactorial 
with an underlying pathophysiology that includes diminished cardiac reserve, rapid 
fluid removal, and autonomic neuropathy [11, 12]. The reported incidence of 
symptomatic hypotension in the general IHD population during or shortly after 
dialysis ranges from 15% to 50% of sessions [13]. Although hypotension was 
frequently observed in our cohort of patients, it rarely required early IHD 
termination. In addition, LVAD monitoring parameters did not reveal any low-flow 
event and only one of the 170 sessions was terminated due to LVAD alarm. These 
results corroborate other retrospective data by Quader, et al and Borrios, et al who 
reported similar rates and types of adverse events [14, 15]. 
The continuous-flow nature of the LVAD’s, such as the Heartmate II, has the 
potential to affect the measurement of both automated and manual cuffs. This is in 
large part due to a reduction in pulse pressure via a constant increase in diastolic 
BP generated by the pump [9]. In addition, many cardiovascular and pump related 
factors, including but not limited to left ventricular contractility, intravascular 
volume, preload, afterload, and pump speed are known to influence pulse 
pressure [16]. The literature has described reduced accuracy in automatic BP 
machines in comparison to other methods, such as invasive monitoring and 
Doppler, in patients with continuous-flow devices. However, if a significant amount 
of residual pulse pressure remains from the native left ventricle (LV) to allow pulse 
pressure to remain above 12.8 ± 4.8, and therefore add pulsatility to the 
continuous-flow provided by the LVAD, automatic BP machines have the ability to 
measure both the systolic and diastolic pressures [9]. Birks et al. demonstrated 
both an improvement in hemodynamic indices after LVAD implantation, likely, due 
to myocardial remodeling from a reduction in the neuroendocrine response that 
corresponds to HF [17]. This was echoed with a study that showed both an 
increase in LV function on echocardiography and a reduction in plasma 
catecholamine levels [18]. Thus, with extended periods of time, recovered cardiac 
function should provide increased native LV function to produce pulse pressure 
gradients detectable by an automated sphygmomanometer. For this reason, 
automatic BP machines were utilized along with Doppler assessment of MAP. 
Inability to register BP using standard sphygmomanometer due to LVAD-induced 
reduction in pulse pressure was a common occurrence and observed in 6 of the 9 
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patients at some point throughout the course of their IHD sessions. Again, during 
these episodes patients were largely asymptomatic and had no change in their 
mental status.   
The most common intervention within the defined hemodynamic instability events 
was the administration of albumin, which was primarily given for hypotension. This 
often occurred in the absence of any documented symptoms of hypoperfusion. 
Although this was the most common intervention in our study it is noteworthy; 
however, that in one randomized controlled trial of maintenance hemodialysis 
patients, the use of 5% albumin was not superior to normal saline for the treatment 
of intradialytic hypotension [19]. Thus, although this was the primary intervention 
used in this study in the inpatient setting, equal efficacy alternatives are available 
for use in other centers and outpatient facilities. The albumin was used in this 
study due to concerns for potential volume overload if normal saline was used. 
Although normal saline is frequently used in outpatient centers, its use has not 
been evaluated in LVAD patients. 
In this study, the prescribed UF and IHD duration were achieved in the majority of 
patients as IHD was terminated early in only 6.5% of IHD sessions. Nausea or 
emesis was experienced in less than 2% of the IHD sessions, which in the general 
IHD population can vary between 6 and 15% [20-22]. Mental status changes never 
occurred in any of the IHD sessions in this study. Sinus tachycardia, defined as 
HR > 100 bpm, was documented in 69 of the IHD sessions (41%). In the general 
IHD population, incidence of cardiac arrhythmias varies between 18-76% [22-27], 
and although the literature shows that ventricular arrhythmias are common in this 
patient population [28], no serious arrhythmias were encountered in this study. 
One-third of patients in this study had CKD prior to their LVAD implant. It is 
interesting to note that Hasin et al. observed an improved glomerular filtration rate 
after LVAD implantation in patients with CKD with abnormal renal function 
secondary to decreased perfusion [29]. 
Out-patient dialysis centers are very cautious to accept end stage renal disease 
patients with LVADs because of the potential complications and absence of 
pulsatile blood pressure for monitoring. Many patients have to stay in the hospitals 
for long time because of the unacceptance by the out-patient dialysis centers. 
Based on our findings and Quader et al. study [14] it appears that patients with 
LVAD are likely to tolerate out-patient in-center HD. However, specific protocols 
and defined parameters to adhere to are needed to be developed and assessed. 
Limitations of this study include those related to any retrospective analysis. The 
most notable, was the reliance on IHD nurse documentation. Although unlikely, 
symptoms, hemodynamic parameters, UF rate, or specific interventions may not 
have been recorded accurately. A sample of 9 patients receiving a total of 170 
hemodialysis sessions may not adequately reflect the true incidence of 
hemodynamic events, symptomatic episodes, or need for therapeutic interventions 
in this patient population.   
Considerations for future investigation include the prospective evaluation of 
patients with LVAD and direct comparison of their hemodynamic profile to other 
patients receiving IHD.  In addition, the efficacy of common strategies to minimize 
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hypotension during IHD has not yet been investigated in LVAD patient population. 
In particular, it is important to compare the effect of albumin to saline infusion, as 
albumin is not commonly used in outpatient in-center dialysis units.  
Conclusion 
Patients with LVAD appear to tolerate in-hospital IHD relatively well compared to 
non-LVAD patients. Symptoms of hemodynamic instability are rare and 
hypotensive episodes are readily responsive to traditional interventions. Further 
longitudinal studies are needed to assess whether with proper monitoring these 
patients can tolerate outpatient IHD well.  
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